Amphetamine-Related Psychiatric Disorders Medication
- Author: Michael F Larson, DO; Chief Editor: Eduardo Dunayevich, MD more...
Medication Summary
Several psychiatric conditions can be associated with amphetamine intoxication and withdrawal, all of which may require different management strategies. However, amphetamine-related psychiatric disorders are typically self-limited and usually remit on their own.
Amphetamine-related psychiatric disorders occur most often during intoxication; therefore, treatment should focus on controlling medical and psychiatric symptoms while eliminating the offending substance. Medical therapy involves stabilizing agitation and minimizing psychosis. Gastric lavage directly removes the amphetamines before they have an opportunity to be absorbed. Medication and charcoal eliminate amphetamines from the gastrointestinal and circulatory systems.
If the induced disorders persist and interfere with the patient's social and occupational functioning, treatment should be related to the remaining psychiatric symptoms. Antidepressants, such as sertraline (Zoloft), fluoxetine (Prozac), paroxetine (Paxil), and citalopram (Celexa), can be used to treat depression. Antimanic agents, such as valproic acid (Depakote), carbamazepine (Tegretol), and lithium carbonate, can be used to treat mania. Anxiety can be treated with nonbenzodiazepine drugs, such as beta-blockers and antimanic agents.
Data from recent studies suggest typical antipsychotics (haloperidol thioridazine, Thorazine, etc) may increase amphetamine and cocaine cravings in patients with dual diagnoses of amphetamine and cocaine abuse. Typical antipsychotics should be used for acute stabilization with the intention of switching to an atypical antipsychotic drug (eg, risperidone, quetiapine, olanzapine, aripiprazole, and ziprasidone) for long-term use.
Some evidence suggests that naltrexone might be helpful in treating those addicted to amphetamines.[7]
For the purposes of this discussion, specific treatment of amphetamine toxicity is reviewed. For further information, please refer to the articles on Depression, Substance-Induced Mood Disorder, Depressed Type, Bipolar Affective Disorder, Schizophrenia, Anxiety Disorders, and Sleeping Disorders.
Antipsychotics
Class Summary
Clinicians should select a high-potency antipsychotic that is available in tablet, liquid, and IM forms for administration in emergency situations. Antipsychotics help control psychotic symptoms and provide rapid tranquilization of the agitated and psychotic patient.
Haloperidol (Haldol)
Provides rapid sedation of agitated anxious patient; available PO and IM, allowing for flexible, emergency administration.
Thiothixene (Navane)
Blocks postsynaptic blockade of CNS dopamine receptors, inhibiting dopamine-mediated effects. PO and IM forms allow for rapid tranquilization.
Benzodiazepines
Class Summary
These drugs are primarily used to sedate agitated patients. Availability in PO, IV, and IM forms allowing the drug to be used in emergency situations. Caution must be used in the violent, aggressive patient because benzodiazepines may cause disinhibition.
Lorazepam (Ativan)
Provides rapid onset and efficacy in sedating aggressive patient; flexible administration in emergency situation.
Chlordiazepoxide (Librium, Libritabs, Mitran)
Depresses all levels of CNS, including limbic and reticular formation, possibly by increasing activity of gamma-aminobutyric acid (GABA) activity, major inhibitory neurotransmitter.
Opiate antagonists
Class Summary
These drugs inhibit the action of opiates.
Naloxone (Narcan)
Used to treat concurrent opiate toxicity. Consider in patients with altered mental status due to opiate overdose. Poorly absorbed PO route and should be administered IM or IV. Available in IV, IM, and SC forms. Use caution to avoid precipitating acute opioid withdrawal in patient using opioids long term.
Beta-blockers
Class Summary
Propranolol (Inderal) is useful in patients who are agitated, anxious, and hyperarousable because of amphetamines. They are temporarily used until the amphetamine is eliminated from the patient's system. For some patients, anxiety can be prolonged, and nonaddictive beta-blockers may be helpful.
Propranolol (Inderal)
Antihypertensive agent useful in psychiatry to treat anxiety and impulse control. Often well tolerated with minimal effect on hemodynamics of blood pressure and pulse.
Expectorants
Class Summary
Expectorants are used to acidify the urine and increase amphetamine excretion when intoxication from amphetamines has resulted in psychiatric and medical complications. These agents are available in PO form, and the patient must be able to swallow or receive a nasogastric tube.
Ammonium chloride (Quelidrine)
Commonly used as OTC expectorant; acidifies urine at high doses. Safe and easy to use.
Adsorbents
Class Summary
These agents, given through a nasogastric tube into the stomach, absorb intentionally and accidentally ingested substances to prevent their further absorption into the systemic circulation.
Activated charcoal suspension (Actidose-aqua, Inst-Aqua, Liquid-Char)
Bottles and tubes. Use long after amphetamine ingestion can reduce systemic levels by adsorbing amphetamines recirculating through gastric mucosa.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, DSM-IV-TR. Washington, DC: American Psychiatric Association; 2000.
Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug Alcohol Depend. Oct 1 2011;118(1):19-22. [Medline].
Thirthalli J, Benegal V. Psychosis among substance users. Curr Opin Psychiatry. May 2006;19(3):239-45. [Medline].
Substance Abuse and Mental Health Services Administration. (2006). Results from the 2005 National Survey on Drug Use and Health: National Findings. Rockville, MD: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies; September 2006. [Full Text].
Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R. Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children. Pediatrics. Feb 2009;123(2):611-6. [Medline].
Alem A, Kebede D, Kullgren G. The prevalence and socio-demographic correlates of khat chewing in Butajira, Ethiopia. Acta Psychiatr Scand Suppl. 1999;397:84-91. [Medline].
Jayaram-Lindström N, Hammarberg A, Beck O, Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry. Nov 2008;165(11):1442-8. [Medline].
Payer DE, Lieberman MD, London ED. Neural correlates of affect processing and aggression in methamphetamine dependence. Arch Gen Psychiatry. Mar 2011;68(3):271-82. [Medline].
Anderson BB, Chen G, Gutman DA, Ewing AG. Dopamine levels of two classes of vesicles are differentially depleted by amphetamine. Brain Res. Mar 30 1998;788(1-2):294-301. [Medline].
Brown ES, Nejtek VA, Perantie DC, et al. Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation. J Clin Psychopharmacol. Aug 2003;23(4):384-8. [Medline].
Cooper N. Inappropriate prescription of methylphenidate. N Z Med J. Oct 10 2003;116(1183):U636. [Medline].
Drug Enforcement Agency. Drug Enforcement Agency: Khat. [Drug Enforcement Administration Web site]. [Full Text].
Farber NB, Hanslick J, Kirby C, et al. Serotonergic agents that activate 5HT2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology. Jan 1998;18(1):57-62. [Medline].
Galanter M, Kleber DH, eds. American Psychiatric Press Textbook of Substance Abuse Treatment. 2nd ed. Arlington, VA: American Psychiatric Press; 1999.
Guze BH, Ferng HK, Szuba MP, Richeimer SH. The Psychiatric Drug Handbook. St Louis, Mo: Mosby-Year; 1995:184-260.
Kaplan HI, Sadock BJ. Comprehensive Textbook of Psychiatry. Baltimore, Md: Lippincott Williams & Wilkins; 1995:792-798.
Kaplan HI, Sadock BJ. Pocket Handbook of Emergency Psychiatric Medicine. Baltimore, Md: Lippincott Williams & Wilkins; 1993:108-110.
Leamon MH, Gibson DR, Canning RD, Benjamin L. Hospitalization of patients with cocaine and amphetamine use disorders from a psychiatric emergency service. Psychiatr Serv. Nov 2002;53(11):1461-6. [Medline].
Methamphetamine abuse and addiction. Research Report Series. National Institute of Health, National Institue on Drug Abuse; January, 2002. [Full Text].
Sekine Y, Minabe Y, Ouchi Y, et al. Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms. Am J Psychiatry. Sep 2003;160(9):1699-701. [Medline].
Sills TL, Greenshaw AJ, Baker GB, Fletcher PJ. Acute fluoxetine treatment potentiates amphetamine hyperactivity and amphetamine-induced nucleus accumbens dopamine release: possible pharmacokinetic interaction. Psychopharmacology (Berl). Feb 1999;141(4):421-7. [Medline].
Srisurapanont M, Jarusuraisin N, Jittiwutikan J. Amphetamine withdrawal: II. A placebo-controlled, randomised, double-blind study of amineptine treatment. Aust N Z J Psychiatry. Feb 1999;33(1):94-8. [Medline].
Thirthalli J, Benegal V. Psychosis among substance users. Curr Opin Psychiatry. May 2006;19(3):239-45. [Medline].

